Press releases

Boston Scientific is the exclusive U.S. distributor of this product for a new treatment option for female stress urinary incontinence

Results to include nine-month data on TAXUS® Liberte™

Lawsuit alleges that the Conor CoStar™ Paclitaxel-Eluting Coronary Stent System infringes a balloon catheter patent owned by Boston Scientific

Court finds Sahajanand's Infinnium paclitaxel-eluting stent infringed two claims of an Angiotech patent

Endoscopic vessel harvesting speeds recovery and reduces pain and scarring; new products offer clinicians more choices to improve patient outcomes

A live webcast and replay of the May 4 conference session will be available

A live webcast and replay of the May 2 conference session will be available

Includes recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs)

Both were members of the board of directors of Guidant Corporation, which was acquired by the Company last week

Company elected to adjust the interest rates due to the closing of the Company's acquisition of Guidant Corporation

Creates a global leader in cardiovascular devices and one of the largest medical technology companies in the world

Transaction scheduled to close tomorrow

"We are very pleased that we achieved record company sales for the quarter," said Jim Tobin, President and Chief Executive Officer

New study seeks to define potential of Precision™ system to treat large population of U.S. migraine sufferers who don't respond adequately to current therapies

Company must also receive antitrust approval from the U.S. Federal Trade Commission (FTC) before it can close the Guidant transaction

A live webcast and replay of the April 18 conference call will be available

Agreement subject to approval by FTC Commissioners

Company's newest addition to its broad portfolio of vascular access products

At separate special meetings today, shareholders of each company have voted overwhelmingly to approve

Features a number of elements designed to enhance steering, handling and tracking during peripheral and coronary procedures

Diabetics and other complex patients see strong results with TAXUS stents

Company plans to appeal the judgment of the Delaware U.S. District Court

Details currently confidential; will become public when the European Commission announces its decision

ISS report notes the "compelling strategic rationale" for the combination of companies

Results of the study were published in today's edition of JAMA

Six-month results are consistent with ARRIVE I data

Complex insulin-treated diabetic population shows numerical trend toward improved MACE outcomes with TAXUS versus Cypher

TAXUS trials continue to deliver positive outcomes in complex cases

Team will lead CRM Group following acquisition of Guidant

Completes Company's application for FDA approval

Results highlight efficacy of TAXUS in most complex lesions and highest risk patients

A live webcast and replay of the March 9 conference session will be available

Shareholders of both companies to vote on March 31, 2006

A live webcast and replay of the March 7 conference session will be available

(February 15, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received reimbursement approval from the French government for its TAXUS

"We reviewed with the FDA a path to resolve the issues they have identified, and we committed to working closely with them to ensure they are resolved," said Tobin

A live webcast and replay of the February 8 conference session will be available

A live webcast and replay of the February 7 conference call will be available

Merger agreement to combine the two companies, creating one of the largest medical technology companies in the world

Study was presented at the Association for Vascular Access (AVA) Annual Conference in Savannah, GA

(January 5, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that President and Chief Executive Officer Jim Tobin has agreed to a request from the Board of Directors to extend...

New device pass-through code is only intended for use in the hospital outpatient setting under Medicare

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the year and fourth quarter ended December 31, 2005.

(December 21, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced it has made a $250,000 gift to Doctors Without Borders, an international medical humanitarian organization, in...

(December 14, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced a $500,000 contribution to the University of Minnesota Foundation to fund the creation of a Boston Scientific...

(December 6, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that two of its senior executives are scheduled to participate in the first annual Massachusetts Conference for...

(November 23, 2005) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in The Fifth Annual Merrill Lynch Med Tech Fundamentals Conference, which is being held on Thursday,...

(November 17, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today the completion of a public offering of $750 million aggregate principal amount of its senior notes under the Company

(November 10, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to begin a prospective, randomized,...

and Vancouver, B.C. (November 8, 2005) -- Boston Scientific Corporation (NYSE: BSX) and Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) announced today that they have jointly received the...